Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

[1]  Soham Gupta,et al.  Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India. , 2010, AIDS research and human retroviruses.

[2]  Ian Sanne,et al.  Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.

[3]  Wayne T. Steward,et al.  Developing useful highly active antiretroviral therapy adherence measures for India: the Prerana study. , 2010, Journal of acquired immune deficiency syndromes.

[4]  J. Nachega,et al.  Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities , 2010, Current opinion in HIV and AIDS.

[5]  D. Katzenstein,et al.  Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India , 2009, Antiviral therapy.

[6]  Y. Tu,et al.  Evolution of HIV‐1 in a patient population failing multiple‐drug therapy , 2009, Microbiology and immunology.

[7]  S. Solomon,et al.  Primary HIV-1 Drug Resistance and Polymorphic Patterns Among Injecting Drug Users (IDUs) in Chennai, Southern India , 2009, Journal of the International Association of Physicians in AIDS Care.

[8]  D. Pillay,et al.  The frequency of HIV-I drug resistance mutations among treatment-naïve individuals at a tertiary care centre in south India , 2009, International journal of STD & AIDS.

[9]  D. Katzenstein,et al.  Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. , 2009, Journal of virological methods.

[10]  R. Schooley,et al.  High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Catherine O'Connor,et al.  Adherence to anti-retroviral therapy among HIV patients in Bangalore, India , 2009, AIDS research and therapy.

[12]  E. Arts,et al.  Adherence and Treatment Response Among HIV-1-Infected Adults Receiving Antiretroviral Therapy in a Rural Government Hospital in Southwestern Uganda , 2009, Journal of the International Association of Physicians in AIDS Care.

[13]  H. Gunthard,et al.  Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[14]  R. Paranjape,et al.  Profile of primary resistance in HIV-1-infected treatment-naive individuals from Western India. , 2008, AIDS research and human retroviruses.

[15]  R. Schooley,et al.  Running with scissors: using antiretroviral therapy without monitoring viral load. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J. Crump,et al.  Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  R. Paranjape,et al.  High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. , 2007, AIDS research and human retroviruses.

[18]  D. Lalloo,et al.  Adherence to Antiretroviral Therapy in Patients Receiving Free Treatment From a Government Hospital in Blantyre, Malawi , 2007, Journal of acquired immune deficiency syndromes.

[19]  Tanvir Ahmed,et al.  Access, adherence, quality and impact of ARV provision to current and ex-injecting drug users in Manipur (India): an initial assessment. , 2007, The International journal on drug policy.

[20]  O. Laeyendecker,et al.  Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda , 2007, AIDS.

[21]  D. G. Saple,et al.  Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  B. Masquelier,et al.  Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. , 2007, AIDS research and human retroviruses.

[23]  M. Wainberg,et al.  High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based Regimens , 2006, Antimicrobial Agents and Chemotherapy.

[24]  G. Guyatt,et al.  Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. , 2006, JAMA.

[25]  F. Ceccherini‐Silberstein,et al.  Clinical and genotypic correlates of mutation K65R in HIV‐infected patients failing regimens not including tenofovir , 2006, Journal of medical virology.

[26]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[27]  D. Hamer,et al.  No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. , 2005, AIDS.

[28]  D. Kempf,et al.  Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. , 2005, The Journal of infectious diseases.

[29]  D. Katzenstein,et al.  HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. , 2005, AIDS research and human retroviruses.

[30]  G. Lucas.  Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. , 2005, The Journal of antimicrobial chemotherapy.

[31]  P. Harrigan,et al.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.

[32]  R. Bollinger,et al.  Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. , 2005, AIDS research and human retroviruses.

[33]  H. Fleury,et al.  Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. , 2004, AIDS research and human retroviruses.

[34]  O. Kirk,et al.  Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study , 2004, HIV medicine.

[35]  D. Bangsberg,et al.  Multiple Validated Measures of Adherence Indicate High Levels of Adherence to Generic HIV Antiretroviral Therapy in a Resource-Limited Setting , 2004, Journal of acquired immune deficiency syndromes.

[36]  D. Descamps,et al.  Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  D. Bangsberg,et al.  Measuring Adherence to Antiretroviral Therapy in a Diverse Population Using a Visual Analogue Scale , 2004, HIV clinical trials.

[38]  Joel E Gallant,et al.  Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[40]  D. Katzenstein,et al.  HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. , 2002, AIDS research and human retroviruses.

[41]  F. Liégeois,et al.  The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study , 2002, AIDS.

[42]  Sundhiya Mandalia,et al.  Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome , 2002, AIDS.

[43]  R. Grant,et al.  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  Zehava Grossman,et al.  Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B , 2001, AIDS.

[45]  A. Zolopa,et al.  Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. , 2001, AIDS.

[46]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[47]  D. Richman,et al.  Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. , 2000 .

[48]  F. Hecht,et al.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.

[49]  D. Richman,et al.  Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. , 2000, The Journal of infectious diseases.

[50]  D Johnson,et al.  The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.

[51]  J. Stephenson.  AIDS researchers target poor adherence. , 1999, JAMA.

[52]  M. Wainberg.  Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. , 1997, Leukemia.

[53]  G. Marín,et al.  Research with Hispanic Populations , 1991 .

[54]  R. Garg,et al.  Adherence to antiretroviral therapy & its determinants amongst HIV patients in India. , 2008, The Indian journal of medical research.

[55]  Tommy F. Liu,et al.  Surfing The Web: Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation , 2006 .